After 10 years at the Diabetes Trials Unit (DTU), Dr. Angelyn Bethel is leaving to pursue career opportunities in the pharmaceutical industry.
Dr. Bethel has the following message for her friends and co-workers: “My decision to leave the DTU was not taken lightly. I have learned so much during my tenure here and hope to apply those lessons in my new position. While I am excited about the new opportunities for me and for my family, I will be sad to say goodbye to this amazing group with whom I have had the privilege of collaborating.
I owe particular thanks to the multi-disciplinary GLINT, TECOS and EXSCEL teams whose hard work and dedication over many years are a testament to the groups' commitment to delivering high quality clinical trials with the potential to improve patient care. I will miss Oxford and will look back on this time with fondness, but I leave with cherished friendships, valued collaborators, and a wealth of experience to inform my next steps.”
Dr. Bethel will be joining Eli Lilly & Company, based in Indianapolis. For contact details, please email email@example.com.